drugset / Trial / NCT03121638

Safety Study of NBP608 in Healthy Adult Volunteers

NCT03121638

Phase 1 Completed 150 enrolled SK Chemicals Co., Ltd.
Non-randomizedParallel-groupOpen-labelPrevention

Summary

* Indication: Protection against varicella and herpes zoster * Study Objectives * Primary: Safety and tolerability assessment after single dose administration of NBP608 * Secondary: immunogenicity assessment after single dose administration of NBP608

Timeline

Start
2012-11
Primary completion
2013-02
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject NBP6081 Unknown 0.5 ml Subcutaneous
Subject NBP6082 Unknown 0.5 ml Subcutaneous
Subject NBP6083 Unknown 0.5 ml Subcutaneous
Comparator Varivax Vaccine 0.5 ml Subcutaneous
Comparator Varivax Vaccine 0.65 ml Subcutaneous